{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:41:48Z","timestamp":1792669308773,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["719445"],"award-info":[{"award-number":["719445"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["719445"],"award-info":[{"award-number":["719445"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["719445"],"award-info":[{"award-number":["719445"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["719445"],"award-info":[{"award-number":["719445"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["719445"],"award-info":[{"award-number":["719445"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["719445"],"award-info":[{"award-number":["719445"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["719445"],"award-info":[{"award-number":["719445"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["719445"],"award-info":[{"award-number":["719445"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["719445"],"award-info":[{"award-number":["719445"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["719445"],"award-info":[{"award-number":["719445"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["719445"],"award-info":[{"award-number":["719445"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["719445"],"award-info":[{"award-number":["719445"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["719445"],"award-info":[{"award-number":["719445"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["719445"],"award-info":[{"award-number":["719445"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["719445"],"award-info":[{"award-number":["719445"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["719445"],"award-info":[{"award-number":["719445"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["719445"],"award-info":[{"award-number":["719445"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["719445"],"award-info":[{"award-number":["719445"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["719445"],"award-info":[{"award-number":["719445"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["719445"],"award-info":[{"award-number":["719445"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["719445"],"award-info":[{"award-number":["719445"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022419","name":"National Institute for Health Research Southampton Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203319"],"award-info":[{"award-number":["NIHR203319"]}],"id":[{"id":"10.13039\/501100022419","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s11136-026-04420-8","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:08:00Z","timestamp":1792667280000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patients with MASH experience worse health-related quality of life: a multinational real-world study using LiverMultiScan"],"prefix":"10.1007","volume":"35","author":[{"given":"Elizabeth","family":"Shumbayawonda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megh","family":"Utsav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitar","family":"Tonev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J","family":"Cuthbertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janisha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metin D","family":"Yalcin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Forton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Ajaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Castelo","family":"Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelte J","family":"Schaapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildo J","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minneke J","family":"Coenraad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Backhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Jayaswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"issue":"3","key":"4420_CR1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver, E.A.S.L., E.A.S.D. European Association for the Study of Diabetes, and E.A.S.O. European Association for the Study of Obesity","year":"2024","unstructured":"European Association for the Study of the Liver, E.A.S.L., E.A.S.D. European Association for the Study of Diabetes, and E.A.S.O. European Association for the Study of Obesity. (2024). EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Journal of Hepatology, 81(3), 492\u2013542.","journal-title":"Journal of Hepatology"},{"issue":"1","key":"4420_CR2","doi-asserted-by":"publisher","first-page":"e2454707","DOI":"10.1001\/jamanetworkopen.2024.54707","volume":"8","author":"P Le","year":"2025","unstructured":"Le, P., et al. (2025). Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050. JAMA Netw Open, 8(1), e2454707.","journal-title":"JAMA Netw Open"},{"key":"4420_CR3","doi-asserted-by":"publisher","unstructured":"Gallo, G., et al. (2025). Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention. International Journal Of Molecular Sciences, 26(16). https:\/\/doi.org\/10.3390\/ijms26168081.","DOI":"10.3390\/ijms26168081"},{"issue":"6","key":"4420_CR4","doi-asserted-by":"publisher","first-page":"100526","DOI":"10.1016\/j.clinme.2025.100526","volume":"25","author":"C Hsu","year":"2025","unstructured":"Hsu, C., & Alazawi, W. (2025). Metabolic dysfunction-associated steatotic liver disease. Clin Med (Lond), 25(6), 100526.","journal-title":"Clin Med (Lond)"},{"issue":"5","key":"4420_CR5","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M., et al. (2016). The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology, 64(5), 1577\u20131586.","journal-title":"Hepatology"},{"issue":"4","key":"4420_CR6","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1177\/0272989X9901900416","volume":"19","author":"P Dolan","year":"1999","unstructured":"Dolan, P. (1999). Whose preferences count? Medical Decision Making, 19(4), 482\u2013486.","journal-title":"Medical Decision Making"},{"issue":"2","key":"4420_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40273-022-01218-7","volume":"41","author":"M Hernandez Alava","year":"2023","unstructured":"Hernandez Alava, M., Pudney, S., & Wailoo, A. (2023). Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study. Pharmacoeconomics, 41(2), 199\u2013207.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"4420_CR8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40273-020-00893-8","volume":"38","author":"AJ Thompson","year":"2020","unstructured":"Thompson, A. J., & Turner, A. J. (2020). A Comparison of the EQ-5D-3L and EQ-5D-5L. Pharmacoeconomics, 38(6), 575\u2013591.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"4420_CR9","doi-asserted-by":"publisher","first-page":"e70280","DOI":"10.1111\/liv.70280","volume":"45","author":"KE Corey","year":"2025","unstructured":"Corey, K. E., et al. (2025). Real-World Assessment of Liver Corrected T1 and Magnetic Resonance Elastography in Predicting Liver Disease Progression. Liver International : Official Journal Of The International Association For The Study Of The Liver, 45(9), e70280.","journal-title":"Liver International : Official Journal Of The International Association For The Study Of The Liver"},{"issue":"8","key":"4420_CR10","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.dld.2025.05.023","volume":"57","author":"MM Phipps","year":"2025","unstructured":"Phipps, M. M., et al. (2025). Multiparametric magnetic resonance imaging may improve detection of patients with at-risk MASH: Real world experience in hepatology clinics. Digestive And Liver Disease : Official Journal Of The Italian Society Of Gastroenterology And The Italian Association For The Study Of The Liver, 57(8), 1646\u20131653.","journal-title":"Digestive And Liver Disease : Official Journal Of The Italian Society Of Gastroenterology And The Italian Association For The Study Of The Liver"},{"key":"4420_CR11","doi-asserted-by":"publisher","unstructured":"Ravela, N., et al. (2025). Early experience with resmetirom to treat metabolic dysfunction-associated steatohepatitis with fibrosis in a real-world setting. Hepatol Commun, 9(4). https:\/\/doi.org\/10.1097\/HC9.0000000000000670.","DOI":"10.1097\/HC9.0000000000000670"},{"issue":"1","key":"4420_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s43856-025-00796-9","volume":"5","author":"E Shumbayawonda","year":"2025","unstructured":"Shumbayawonda, E., et al. (2025). Utility and cost-effectiveness of LiverMultiScan for MASLD diagnosis: a real-world multi-national randomised clinical trial. Commun Med (Lond), 5(1), 74.","journal-title":"Commun Med (Lond)"},{"issue":"4","key":"4420_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16040","volume":"16","author":"M Stevenson","year":"2012","unstructured":"Stevenson, M., et al. (2012). Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation. Health Technology Assessment, 16(4), 1\u2013174.","journal-title":"Health Technology Assessment"},{"issue":"10","key":"4420_CR14","doi-asserted-by":"publisher","first-page":"e19189","DOI":"10.2196\/19189","volume":"9","author":"D Tonev","year":"2020","unstructured":"Tonev, D., et al. (2020). The Effect of Multi-Parametric Magnetic Resonance Imaging in Standard of Care for Nonalcoholic Fatty Liver Disease: Protocol for a Randomized Control Trial. JMIR Res Protoc, 9(10), e19189.","journal-title":"JMIR Res Protoc"},{"issue":"4","key":"4420_CR15","doi-asserted-by":"publisher","first-page":"e0214921","DOI":"10.1371\/journal.pone.0214921","volume":"14","author":"V Bachtiar","year":"2019","unstructured":"Bachtiar, V., et al. (2019). Repeatability and reproducibility of multiparametric magnetic resonance imaging of the liver. PLoS One, 14(4), e0214921.","journal-title":"PLoS One"},{"issue":"10","key":"4420_CR16","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman, M., et al. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality Of Life Research, 20(10), 1727\u20131736.","journal-title":"Quality Of Life Research"},{"key":"4420_CR17","doi-asserted-by":"publisher","unstructured":"Ludwig, K., Graf, J. M., Schulenburg, & Greiner, W. (2018). German Value Set for the EQ-5D-5L. Pharmacoeconomics, 36(6): pp. 663\u2013674. https:\/\/doi.org\/10.1007\/s40273-018-0615-8.","DOI":"10.1007\/s40273-018-0615-8"},{"issue":"4","key":"4420_CR18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","volume":"19","author":"MM Versteegh","year":"2016","unstructured":"Versteegh, M. M., et al. (2016). Dutch Tariff for the Five-Level Version of EQ-5D. Value In Health : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research, 19(4), 343\u2013352.","journal-title":"Value In Health : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research"},{"issue":"12","key":"4420_CR19","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1007\/s11136-019-02226-5","volume":"28","author":"PL Ferreira","year":"2019","unstructured":"Ferreira, P. L., et al. (2019). A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set. Quality of Life Research, 28(12), 3163\u20133175.","journal-title":"Quality of Life Research"},{"issue":"9","key":"4420_CR20","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.jval.2021.03.009","volume":"24","author":"BA van Hout","year":"2021","unstructured":"van Hout, B. A., & Shaw, J. W. (2021). Mapping EQ-5D-3L to EQ-5D-5L. Value In Health : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research, 24(9), 1285\u20131293.","journal-title":"Value In Health : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research"},{"key":"4420_CR21","doi-asserted-by":"publisher","unstructured":"Rowen, D., et al. (2026). A UK value set for the EQ-5D-5L. Value In Health : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research. https:\/\/doi.org\/10.1016\/j.jval.2026.03.008.","DOI":"10.1016\/j.jval.2026.03.008"},{"key":"4420_CR22","doi-asserted-by":"crossref","unstructured":"Mack, C., Su, Z., & Westreich, D. (2018). Managing Missing Data in Patient Registries: Addendum to Registries for Evaluating Patient Outcomes. A User\u2019s Guide (3rd ed.). Agency for Healthcare Research and Quality.","DOI":"10.23970\/AHRQREGISTRIESMISSINGDATA"},{"issue":"3","key":"4420_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/bimj.201700067","volume":"60","author":"G Heinze","year":"2018","unstructured":"Heinze, G., Wallisch, C., & Dunkler, D. (2018). Variable selection - A review and recommendations for the practicing statistician. Biometrical Journal. Biometrische Zeitschrift, 60(3), 431\u2013449.","journal-title":"Biometrical Journal. Biometrische Zeitschrift"},{"issue":"1","key":"4420_CR24","doi-asserted-by":"publisher","first-page":"e000262","DOI":"10.1136\/fmch-2019-000262","volume":"8","author":"MZI Chowdhury","year":"2020","unstructured":"Chowdhury, M. Z. I., & Turin, T. C. (2020). Variable selection strategies and its importance in clinical prediction modelling. Fam Med Community Health, 8(1), e000262.","journal-title":"Fam Med Community Health"},{"issue":"11","key":"4420_CR25","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.cgh.2021.09.041","volume":"20","author":"A Andersson","year":"2022","unstructured":"Andersson, A., et al. (2022). Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis. Clinical Gastroenterology And Hepatology, 20(11), 2451\u20132461. e3.","journal-title":"Clinical Gastroenterology And Hepatology"},{"issue":"4","key":"4420_CR26","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/hep.29639","volume":"67","author":"C Caussy","year":"2018","unstructured":"Caussy, C., et al. (2018). Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology, 67(4), 1348\u20131359.","journal-title":"Hepatology"},{"issue":"3","key":"4420_CR27","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","volume":"77","author":"N Alkhouri","year":"2022","unstructured":"Alkhouri, N., et al. (2022). Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. Journal Of Hepatology, 77(3), 607\u2013618.","journal-title":"Journal Of Hepatology"},{"key":"4420_CR28","unstructured":"National Institute for Health and Care Excellence (NICE) (2023). MRI-based technologies for assessing non-alcoholic fatty liver disease."},{"issue":"10","key":"4420_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/KGJU3398","volume":"27","author":"R Bresnahan","year":"2023","unstructured":"Bresnahan, R., et al. (2023). Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation. Health Technology Assessment, 27(10), 1\u2013115.","journal-title":"Health Technology Assessment"},{"issue":"13","key":"4420_CR30","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1016\/j.cgh.2020.04.046","volume":"18","author":"N Samala","year":"2020","unstructured":"Samala, N., et al. (2020). Decreased Quality of Life Is Significantly Associated With Body Composition in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology And Hepatology, 18(13), 2980\u20132988e4.","journal-title":"Clinical Gastroenterology And Hepatology"},{"issue":"12","key":"4420_CR31","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1016\/j.cgh.2023.04.018","volume":"21","author":"M Papatheodoridi","year":"2023","unstructured":"Papatheodoridi, M., et al. (2023). Health-related Quality of Life in Patients With Nonalcoholic Fatty Liver Disease: A Prospective Multi-center UK Study. Clinical Gastroenterology And Hepatology, 21(12), 3107\u20133114e3.","journal-title":"Clinical Gastroenterology And Hepatology"},{"key":"4420_CR32","doi-asserted-by":"publisher","first-page":"100033","DOI":"10.1016\/j.puhip.2020.100033","volume":"1","author":"T Zoe","year":"2020","unstructured":"Zoe, T., et al. (2020). Health related quality of life in individuals at high risk of chronic liver disease: Impact of a community diagnostic pathway. Public Health Pract (Oxf), 1, 100033.","journal-title":"Public Health Pract (Oxf)"},{"issue":"6","key":"4420_CR33","doi-asserted-by":"publisher","first-page":"e0312650","DOI":"10.1371\/journal.pone.0312650","volume":"20","author":"T Fu","year":"2025","unstructured":"Fu, T., et al. (2025). Comparative association between NAFLD and MAFLD with cardiovascular events and mortality: Evidence from observational studies. PLoS One, 20(6), e0312650.","journal-title":"PLoS One"},{"issue":"3","key":"4420_CR34","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.jhep.2025.04.020","volume":"83","author":"GN Ioannou","year":"2025","unstructured":"Ioannou, G. N. (2025). MASLD and non-liver-related mortality: Association, independent association and causality. Journal Of Hepatology, 83(3), 611\u2013614.","journal-title":"Journal Of Hepatology"},{"issue":"7","key":"4420_CR35","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1038\/s41591-025-03654-2","volume":"31","author":"E Jackson","year":"2025","unstructured":"Jackson, E., et al. (2025). Cardiac and liver impairment on multiorgan MRI and risk of major adverse cardiovascular and liver events. Nature Medicine, 31(7), 2289\u20132296.","journal-title":"Nature Medicine"},{"issue":"5","key":"4420_CR36","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.jhep.2023.05.046","volume":"79","author":"A Roca-Fernandez","year":"2023","unstructured":"Roca-Fernandez, A., et al. (2023). Liver disease is a significant risk factor for cardiovascular outcomes - A UK Biobank study. Journal Of Hepatology, 79(5), 1085\u20131095.","journal-title":"Journal Of Hepatology"},{"key":"4420_CR37","unstructured":"NHS England Health Trends in England. Cardiovascular disease in England 2026 [cited 2026 10 April]; Available from: https:\/\/fingertips.phe.org.uk\/static-reports\/health-trends-in-england\/England\/cardiovascular_disease.html"},{"key":"4420_CR38","unstructured":"Office for Health Improvements and Disparities (UK) (2024). Official Statistics - Liver disease profile, December 2024 update."},{"issue":"6","key":"4420_CR39","doi-asserted-by":"publisher","first-page":"e70920","DOI":"10.1002\/hsr2.70920","volume":"8","author":"L Shakeel","year":"2025","unstructured":"Shakeel, L., Shaukat, A., & Akilimali, A. (2025). Resmetirom: A Breakthrough in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Health Sci Rep, 8(6), e70920.","journal-title":"Health Sci Rep"},{"issue":"4","key":"4420_CR40","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1097\/HEP.0000000000001084","volume":"81","author":"ZM Younossi","year":"2025","unstructured":"Younossi, Z. M., et al. (2025). Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. Hepatology, 81(4), 1318\u20131327.","journal-title":"Hepatology"},{"issue":"1","key":"4420_CR41","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1080\/13696998.2025.2550113","volume":"28","author":"M Hancock","year":"2025","unstructured":"Hancock, M., et al. (2025). Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States. Journal Of Medical Economics, 28(1), 1370\u20131387.","journal-title":"Journal Of Medical Economics"},{"issue":"11","key":"4420_CR42","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1007\/s00330-015-3731-2","volume":"25","author":"E Zhang","year":"2015","unstructured":"Zhang, E., et al. (2015). Cost-utility analysis of nonalcoholic steatohepatitis screening. European Radiology, 25(11), 3282\u20133294.","journal-title":"European Radiology"},{"issue":"1","key":"4420_CR43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12072-018-9907-5","volume":"13","author":"S Wu","year":"2019","unstructured":"Wu, S., et al. (2019). Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis. Hepatology International, 13(1), 91\u2013101.","journal-title":"Hepatology International"},{"key":"4420_CR44","unstructured":"EuroQol Research Foundation Population norms. [cited 2026 27 July]; Available from: https:\/\/euroqol.org\/information-and-support\/resources\/population-norms\/"},{"key":"4420_CR45","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1477-7525-8-18","volume":"8","author":"O Solli","year":"2010","unstructured":"Solli, O., Stavem, K., & Kristiansen, I. S. (2010). Health-related quality of life in diabetes: The associations of complications with EQ-5D scores. Health And Quality Of Life Outcomes, 8, 18.","journal-title":"Health And Quality Of Life Outcomes"},{"issue":"6","key":"4420_CR46","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","volume":"95","author":"A Lloyd","year":"2006","unstructured":"Lloyd, A., et al. (2006). Health state utilities for metastatic breast cancer. British Journal Of Cancer, 95(6), 683\u2013690.","journal-title":"British Journal Of Cancer"},{"issue":"2","key":"4420_CR47","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/17453670710015094","volume":"79","author":"O Strom","year":"2008","unstructured":"Strom, O., et al. (2008). Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthopaedica, 79(2), 269\u2013280.","journal-title":"Acta Orthopaedica"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-026-04420-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-026-04420-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-026-04420-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:08:03Z","timestamp":1792667283000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-026-04420-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["4420"],"URL":"https:\/\/doi.org\/10.1007\/s11136-026-04420-8","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"25 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"As this study was a multicentre randomised controlled trial with human participants, ethics approval was required in each country involved in the study. Relevant institutional approvals were obtained from the following committees with associated reference numbers prior to study commencement:","order":1,"name":"Ethics","label":"Compliance with ethical standards","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data and analytic methods used in this study remain the property of the study sponsors. All deidentified participant data may be made available to other researchers upon request following permission, investigator support and following a signed data access agreement.","order":2,"name":"Ethics","label":"Data sharing statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ES, MH, AJ, are employees of Perspectum Ltd. AJT is a consultant for Perspectum. CDB has received research funding from Echosens and was supported in part by the Southampton National Institute for Health Research Biomedical Research Centre (NIHR203319), U.K.All other co-authors have no conflicts of interest to declare relevant to this work.","order":3,"name":"Ethics","label":"<b>Competing interests<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"312"}}